In this direction, we employed a thorough bioinformatic approach, which in addition to revealing the dysregulation of TGFβ-1 and CXCR4 in various cancers also revealed that TGFβ-1 and CXCR4 when targeted using the respective inhibitors in combination displayed synergy, which is desirable for the better treatment of breast cancer. This evidence concerns the gene TGFB1 and breast cancer.